Search by Drug Name, NDC or Jcode
Internal Navigation
HCPCS Details
HCPC | J0179 |
Short Description | Inj, brolucizumab-dbll, 1 mg |
Long Description | Injection, brolucizumab-dbll, 1 mg |
Pricing indicator | 51 |
Coverage code | C |
ASC payment group code | YY |
BETOS2 code | O1E |
Action code | N |
Type of service | 1 |
Effective date | 2020-01-01 |
Date Added | 2020-01-01 |
HCPCS/NDC Cross-Walk
NDC | HCPC | Description | Drug Name | Labeler Name | HCPCS Dosage | PKG Size | PKG QTY | Bill Units | Bill Units PKG |
---|---|---|---|---|---|---|---|---|---|
00078082760 | J0179 | Inj, brolucizumab-dbll, 1 mg | Beovu | NOVARTIS PHARMACEUTICALS CORP. | 1 MG | 0.05 | 1 | 6 | 6 |
00078082761 | J0179 | Inj, brolucizumab-dbll, 1 mg | Beovu | NOVARTIS PHARMACEUTICALS CORPORATION | 1 MG | 0.05 | 1 | 6 | 6 |
HCPCS Billing Calculator
Dosage given to patient (per dose) | |
---|---|
HCPCS Dosage | 1 MG |
HCPCS/CPT Billing Units | 1 |
Total doses ordered | |
Billing Units | 1 |
Drug Details
-
Brolucizumab-dbll injection is used to treat wet age-related macular degeneration (AMD; an ongoing disease of the eye that causes loss of the ability to see straight ahead and may make it more difficult to read, drive, or perform other daily activities). Brolucizumab-dbll injection is also used to treat diabetic macular edema (DME; an eye disease caused by diabetes that can lead to vision loss). Brolucizumab-dbll is in a class of medications called vascular endothelial growth factor A (VEGF-A) antagonists. It works by stopping abnormal blood vessel growth and leakage in the eye(s) that may cause vision loss.